Autumn Glory Partners LLC Acquires New Shares in Zoetis Inc. $ZTS

Key Points

• Autumn Glory Partners LLC acquired 4,704 shares of Zoetis Inc. valued at approximately $734,000 in the second quarter, indicating growing institutional interest in the stock.
• Several hedge funds have significantly increased their stakes in Zoetis, with 92.80% of the stock now owned by institutional investors.
• Analyst ratings for Zoetis vary, with five analysts rating it as a "Buy" and five as a "Hold", and an average price target of $200.88 reflecting mixed market sentiments.

Autumn Glory Partners LLC bought a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 4,704 shares of the company's stock, valued at approximately $734,000.

Other hedge funds have also added to or reduced their stakes in the company. Sound Income Strategies LLC raised its stake in Zoetis by 54.3% during the 2nd quarter. Sound Income Strategies LLC now owns 432 shares of the company's stock valued at $67,000 after buying an additional 152 shares during the last quarter. Portside Wealth Group LLC increased its stake in shares of Zoetis by 24.7% in the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock worth $5,550,000 after purchasing an additional 6,672 shares in the last quarter. Tandem Investment Advisors Inc. increased its stake in shares of Zoetis by 100.3% in the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock worth $65,140,000 after purchasing an additional 198,089 shares in the last quarter. Soros Capital Management LLC increased its stake in shares of Zoetis by 32.0% in the 1st quarter. Soros Capital Management LLC now owns 17,441 shares of the company's stock worth $2,872,000 after purchasing an additional 4,230 shares in the last quarter. Finally, Flagship Harbor Advisors LLC increased its stake in shares of Zoetis by 31.2% in the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock worth $1,217,000 after purchasing an additional 1,760 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ZTS. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Argus restated a "buy" rating and issued a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Weiss Ratings restated a "hold (c-)" rating on shares of Zoetis in a research note on Saturday, September 27th. Finally, Piper Sandler upped their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Five analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, Zoetis currently has an average rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Trading Down 0.0%

Shares of Zoetis stock opened at $146.45 on Monday. The company has a market capitalization of $64.91 billion, a P/E ratio of 25.21, a P/E/G ratio of 2.35 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The company has a fifty day moving average of $149.79 and a 200 day moving average of $155.02. Zoetis Inc. has a fifty-two week low of $139.34 and a fifty-two week high of $196.55.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the prior year, the firm posted $1.56 EPS. Zoetis's quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.